Mona-Rita Yacoub

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8338079/publications.pdf

Version: 2024-02-01

60 papers 1,624 citations

361296 20 h-index 315616 38 g-index

61 all docs

61 docs citations

61 times ranked

2509 citing authors

#	Article	IF	CITATIONS
1	Dupilumab as a $\langle i \rangle$ potential $\langle i \rangle$ steroid-sparing treatment for IgG4-related disease. Annals of the Rheumatic Diseases, 2022, 81, e24-e24.	0.5	7
2	Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis. Clinical Immunology Communications, 2022, 2, 23-29.	0.5	2
3	Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study. Nutrients, 2022, 14, 1513.	1.7	13
4	Hypereosinophilia management in patients with type 2 chronic rhinosinusitis treated with dupilumab: preliminary results. European Archives of Oto-Rhino-Laryngology, 2022, 279, 5231-5238.	0.8	9
5	COVID‶9 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 887-892.	2.7	69
6	Systemic allergic reactions induced by labile plantâ€food allergens: Seeking potential cofactors. A multicenter study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1473-1479.	2.7	28
7	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organization Journal, 2021, 14, 100509.	1.6	14
8	Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVIDâ€19?. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 961-962.	2.7	3
9	Correspondence on †Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'. Annals of the Rheumatic Diseases, 2021, 80, e159-e159.	0.5	18
10	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3997-4004.	2.0	74
11	Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19. Clinical Microbiology and Infection, 2021, 27, 1190-1192.	2.8	9
12	Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine. Vaccine, 2021, 39, 6464-6469.	1.7	8
13	Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases. Vaccines, 2021, 9, 1147.	2.1	8
14	Severe asthma: One disease and multiple definitions. World Allergy Organization Journal, 2021, 14, 100606.	1.6	18
15	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). World Allergy Organization Journal, 2020, 13, 100464.	1.6	30
16	Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis. Journal of the Neurological Sciences, 2020, 418, 117104.	0.3	2
17	SIRM-SIAAIC consensus, an Italian document on management of patients at risk of hypersensitivity reactions to contrast media. Clinical and Molecular Allergy, 2020, 18, 13.	0.8	7
18	Caring with compassion during COVID-19. Palliative and Supportive Care, 2020, 18, 403-404.	0.6	8

#	Article	IF	CITATIONS
19	Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. Respiratory Medicine, 2020, 166, 105947.	1.3	55
20	IgG4-related disease and allergen-specific immunotherapy. Annals of Allergy, Asthma and Immunology, 2020, 124, 631-633.	0.5	9
21	Characteristics and treatment regimens across ERS SHARP severe asthma registries. European Respiratory Journal, 2020, 55, 1901163.	3.1	56
22	Post-COVID-19 follow-up clinic: depicting chronicity of a new disease. Acta Biomedica, 2020, 91, 22-28.	0.2	47
23	337.â€∱MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A SINGLE CENTRE REAL-LIFE EXPERIENCE. Rheumatology, 2019, 58, .	0.9	O
24	SATO177â€CLINICAL AND EPIDEMIOLOGICAL RELEVANCE OF ALLERGY IN SYSTEMIC LUPUS ERYTHEMATOSUS: A OBSERVATIONAL STUDY., 2019, , .	AN	0
25	Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience. Annals of Allergy, Asthma and Immunology, 2018, 120, 318-323.	0.5	21
26	Diamine Oxidase Supplementation in Chronic Spontaneous Urticaria: A Randomized, Double-Blind Placebo-Controlled Study. International Archives of Allergy and Immunology, 2018, 176, 268-271.	0.9	29
27	Eosinophils from Physiology to Disease: A Comprehensive Review. BioMed Research International, 2018, 2018, 1-28.	0.9	182
28	Evaluation of basophil activation test in suspected food hypersensitivity. Cytometry Part B - Clinical Cytometry, 2017, 92, 279-285.	0.7	4
29	Rituximab hypersensitivity in IgG4-related disease: successful desensitization in a patient with IgG4 rheumatoid factor. International Journal of Rheumatic Diseases, 2017, 20, 276-279.	0.9	12
30	Histamine release positive test associates with disease remission in chronic spontaneous urticaria: a proof-of-concept study. European Annals of Allergy and Clinical Immunology, 2017, 49, 154.	0.4	5
31	Drug induced exfoliative dermatitis: state of the art. Clinical and Molecular Allergy, 2016, 14, 9.	0.8	14
32	Guidelines for the use and interpretation of diagnostic methods in adult food allergy. Clinical and Molecular Allergy, 2015, 13, 27.	0.8	30
33	Are atopy and eosinophilic bronchial inflammation associated with relapsing forms of chronic rhinosinusitis with nasal polyps?. Clinical and Molecular Allergy, 2015, 13, 23.	0.8	14
34	Optimal management of DRESS syndrome in course of infectious endocarditis. Annals of Allergy, Asthma and Immunology, 2013, 110, 303-305.	0.5	9
35	InÂvivo tests with "Tahini―sauce: new allergenic source to evaluate IgE-mediated hypersensitivity to sesame. Annals of Allergy, Asthma and Immunology, 2013, 110, 209-210.	0.5	17
36	Resuscitation Fluids. New England Journal of Medicine, 2013, 369, 2461-2463.	13.9	37

#	Article	IF	CITATIONS
37	Italian Study on Buckwheat Allergy: Prevalence and Clinical Features of Buckwheat-Sensitized Patients in Italy. International Journal of Immunopathology and Pharmacology, 2013, 26, 801-806.	1.0	16
38	Effects of Sublingual Immunotherapy on Allergic Inflammation: An Update. Inflammation and Allergy: Drug Targets, 2012, 11, 285-291.	1.8	10
39	Immune Mechanisms of Allergen-Specific Immunotherapy. The Open Allergy Journal, 2012, 5, 47-52.	0.5	2
40	Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1563-1569.	2.7	49
41	Omega-5 gliadin anaphylaxis: an integrated diagnostic approach. European Annals of Allergy and Clinical Immunology, 2011, 43, 92-4.	0.4	2
42	Pulmonary Rehabilitation as Evaluated by Clinical Trials: An Overview. Reviews on Recent Clinical Trials, 2010, 5, 76-84.	0.4	8
43	Six-Minute Walk Test cut-off value identifying COPD patients with physical disability: a pilot study. Monaldi Archives for Chest Disease, 2010, 73, 176-7.	0.3	0
44	Safety of sublingual immunotherapy started during the pollen season. Current Medical Research and Opinion, 2009, 25, 103-107.	0.9	16
45	EAACI position paper on occupational rhinitis. Respiratory Research, 2009, 10, 16.	1.4	115
46	Occupational rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 969-980.	2.7	152
47	Usefulness of induced sputum in investigating occupational asthma with normal responsiveness to methacholine: A case report. Journal of Allergy and Clinical Immunology, 2008, 122, 831-832.	1.5	7
48	Effects of Sublingual Immunotherapy on Allergic Inflammation. Inflammation and Allergy: Drug Targets, 2008, 7, 167-172.	1.8	6
49	Effect of noninvasive mechanical ventilation in elderly patients with hypercapnic acute-on-chronic respiratory failure and a do-not-intubate order. International Journal of COPD, 2008, Volume 3, 797-801.	0.9	27
50	Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium. International Journal of COPD, 2008, Volume 3, 123-126.	0.9	9
51	Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Archives for Chest Disease, 2008, 69, 78-80.	0.3	23
52	Incidence and characteristics of hospital-acquired pneumonia in a pulmonary rehabilitation setting. Medical Science Monitor, 2008, 14, CR196-8.	0.5	1
53	Assessment of impairment/disability due to occupational asthma through a multidimensional approach. European Respiratory Journal, 2007, 29, 889-896.	3.1	54
54	World Trade Center disaster: short- and medium-term health outcome. Monaldi Archives for Chest Disease, 2007, 67, 154-8.	0.3	2

#	Article	IF	CITATIONS
55	Evaluation of Eosinophilic Inflammation in Patients with Suspected Occupational Asthma or Rhinitis. Journal of Allergy and Clinical Immunology, 2006, 117, S268.	1.5	0
56	Role of the Chemokine Receptors CXCR3 and CCR4 in Human Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 310-317.	2.5	79
57	Occupational Asthma and Occupational Rhinitis in Hairdressers. Chest, 2005, 128, 3590-3598.	0.4	129
58	Occupational eosinophilic bronchitis. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 1542-1544.	2.7	25
59	Occupational asthma due to bethabara wood dust. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 1544-1545.	2.7	8
60	Asthma caused by cyanoacrylate used in a leisure activity. Journal of Allergy and Clinical Immunology, 2005, 116, 462-462.	1.5	11